Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. reported that its Chairman and CEO, Amir Heshmatpour, recently bought approximately $300,000 of NTHI stock, signaling management’s confidence in the company. The update also explains the components of the company’s 2025 net loss and its current cash use.
For 2025, NeOnc recorded a net loss of about $62 million, with roughly 73% tied to non-cash stock-based compensation and one-time listing-related advisory fees. These non-cash and non-recurring items totaled $45.2 million, leaving normalized ongoing cash operating expenses of about $10.1 million. NeOnc also raised approximately $13.0 million in a Q1 2026 private placement, using part of the proceeds to repay short-term convertible debt and settle accrued obligations, and highlighted a reconciliation showing 2025 core operating cash burn of roughly $10.1 million.
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders. The 680,558 shares consist of 340,279 currently issued shares and 340,279 shares issuable upon exercise of Warrants exercisable at $9.00 per share and expiring five years from issuance. The resale registration covers shares issued in several private placement closings and is being filed to satisfy registration rights granted to the selling holders. The Company will not receive proceeds from resales by the selling holders; it would receive proceeds only if Warrants are exercised for cash rather than on a cashless basis. Common stock outstanding was 24,911,482 shares as of April 8, 2026, and the last reported Nasdaq sale price was $5.37 per share.
NEONC Technologies Holdings' Chief Accounting Officer David Suh Jr. reported recent stock activity. On April 9, 2026, he made an open-market purchase of 200 shares of common stock at $5.00 per share, bringing his direct holdings to 111,866 shares.
On March 1, 2026, he was granted an aggregate 170,000 shares of restricted common stock under the company’s 2023 Equity Incentive Plan. Of these, 53,333 shares vested immediately, 58,333 shares are scheduled to vest on the one-year anniversary of the grant, and the remaining shares are performance-based, with the final number deliverable depending on achievement of specified performance criteria.
NEONC TECHNOLOGIES HOLDINGS, INC. executive David Suh Jr., the Chief Accounting Officer, has filed an initial Form 3 as a reporting person for the company’s stock. The filing shows no reported transactions or holdings in the issuer’s securities at this time based on the provided data.
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders, consisting of 340,279 issued shares and 340,279 shares issuable upon exercise of warrants. The registration covers resales by holders who acquired shares and five-year warrants in private placements in January–March 2026. The Company will not receive proceeds from resales; it may receive exercise proceeds if warrants are exercised. Shares outstanding were 24,911,482 as of April 8, 2026. The prospectus discloses outstanding warrants to purchase 1,815,528 shares exercisable at $9.00 per share and notes recent operating losses and tax liabilities.
NeOnc Technologies Holdings, Inc. established an at-the-market equity program allowing it to sell up to $75,000,000 of common stock through BTIG, LLC and A.G.P./Alliance Global Partners as placement agents. Sales may be made from time to time on the Nasdaq Global Market or other existing U.S. trading markets.
The company will pay the placement agents a cash commission equal to 3.0% of the gross sales price of shares sold and reimburse specified expenses. The shares will be issued under NeOnc’s previously filed Registration Statement on Form S-3 (File No. 333-294845), which was declared effective on April 9, 2026, and a related prospectus supplement filed April 10, 2026.
NeOnc Technologies Holdings, Inc. files a prospectus supplement to offer up to $75,000,000 of Common Stock in an at-the-market program through BTIG, LLC and A.G.P./Alliance Global Partners under an Equity Distribution Agreement dated April 10, 2026. The company may sell shares from time to time at prevailing market prices; proceeds are intended to pay approximately $7.0 million of withholding tax obligations, fund clinical trials, and provide working capital. The offering cites up to 38,877,962 shares outstanding after this offering under an illustrative sale assumption and reports 24,911,482 shares outstanding currently. Sales are discretionary, there is no minimum offering amount, and Placement Agents will receive a 3.0% commission on gross proceeds.
NEONC Technologies Holdings, Inc. president, director, and more-than-10% owner Amir F. Heshmatpour bought additional common shares in the open market. On April 10, 2026, he purchased 10,000 shares of common stock in open-market transactions at a weighted average price of $4.895 per share, with individual trades ranging from $4.84 to $4.95 per share.
Following this purchase, Heshmatpour holds 3,042,000 common shares directly, a figure that includes 275,000 shares held by certain immediate family members for which he disclaims beneficial ownership except for any pecuniary interest. The filing also reports indirect holdings of 256,120 shares through HCWG LLC, 550,000 shares through KIG LLC, and 3,714,020 shares through AFH Holding & Advisory, LLC, where he is the sole member and manager. The 10,000-share buy is relatively small compared with these multi-million-share positions.